Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same

Patent metadata

Field	Value
Publication number	US-9616130-B2
Application number	US-201514799430-A
Country	US
Kind code	B2
Filing date	Jul 14, 2015
Priority date	Jul 19, 2006
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono-and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake.

First claim

We claim:

1. A pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient that is present as a solid dispersion, at least one pharmaceutically acceptable polymer and a solubilizing composition, the solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester, wherein melt-processing comprises melting the pharmaceutically acceptable polymer bv heating above the softening point of the pharmaceutically acceptable polymer and allowing the other components to dissolve in the melt.

2. The dosage form of claim 1 , wherein the tocopheryl compound is alpha tocopheryl polyethylene glycol succinate.

3. The dosage form of claim 1 , wherein the alkylene glycol fatty acid monoester is propylene glycol monolaurate.

4. The dosage form of claim 1 , wherein the weight ratio of tocopheryl compound and alkylene glycol fatty acid ester is in the range of from 9:1 to 1:9.

5. The dosage form of claim 1 which comprises, relative to the weight of the melt-processed mixture, from about 0.5 to 40% by weight of said active ingredient, 40 to 99% by weight of said pharmaceutically acceptable polymer, 0.5 to 20% by weight of said solubilizing composition, and 0 to 15% by weight of additives.

6. The dosage form of claim 1 which comprises, relative to the weight of the melt-processed mixture, from about 15 to 40% by weight of said active ingredient, 40 to 70% by weight of said pharmaceutically acceptable polymer, 4 to 20% by weight of said solubilizing composition, and 0 to 15% by weight of additives.

7. The dosage form of claim 1 which comprises, relative to the weight of the melt-processed mixture, from about 0.5 to 15% by weight of said active ingredient, 60 to 99% by weight of said pharmaceutically acceptable polymer, 0.5 to 15% by weight of said solubilizing composition, and 0 to 15% by weight of additives.

8. The dosage form of claim 1 , wherein the active ingredient is an HIV protease inhibitor or a combination of HIV protease inhibitors.

9. The dosage form of claim 8 , wherein said HIV protease inhibitor is selected from the group consisting of: 2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir);
(2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (lopinavir);
N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);
N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);
5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)phenylmethyl-hexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;
1-Naphthoxyacetyl-beta-methylthio-Ala-(2S,3S)3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4t-butylamide;
5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;
[1S-[1R-(R-),2S*])-N′-[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;
amprenavir (VX-478); DMP-323; DMP-450; AG1343 (nelfinavir);
atazanavir (BMS 232,632);
tipranavir;
palinavir;
darunavir (TMC-114);
R0033-4649;
fosamprenavir (GW433908);
P-1946;
tert-butyl[3-hydroxy-4[2-hydroxy-4-[4-(morpholin-4-ylcarbonylmethoxy)phenyl]-3-tert-butoxycarbonylamino-butyl]amino-1-phenyl-butan-2-yl]aminoformate (BMS 186,318);
SC-55389a;
BILA 1906 BS;
N-[3-[1-(2-hydroxy-4-oxo-6-phenethyl-6-propyl-5H-pyran-3-yl)propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide (tipranavir, U-140690);
or combinations thereof.

10. The dosage form of claim 9 , wherein said HIV protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)amino-1,6-diphenyl-3-hydroxyhexane (ritonavir).

11. The dosage form of claim 9 wherein said HIV protease inhibitor is (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)-amino-3-hydroxy-5-[2S-(1-tetrahydropyrim id-2-onyl)-3-methyl-butanoyl]amino-1,6-diphenylhexane (lopinavir).

12. The dosage form of claim 9 , wherein said HIV protease inhibitor is a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)-carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl] amino-1,6-diphenylhexane (lopinavir).

13. The solid dosage form of claim 1 , wherein said pharmaceutically acceptable polymer is a homopolymer or copolymer of N-vinyl pyrrolidone.

14. The solid dosage form of claim 13 , wherein said pharmaceutically acceptable polymer is a copolymer of N-vinyl pyrrolidone and vinyl acetate.

15. The solid dosage form of claim 1 , containing at least one additive selected from flow regulators, disintegrants, bulking agents and lubricants.

16. The solid dosage form of claim 1 , wherein the melt-processed mixture has a Tg of 10 ° C. or higher.

17. A method of preparing a solid dosage form of claim 5 which comprises:
a) melting the pharmaceutically acceptable polymer by heating above the softening point of the pharmaceutically acceptable polymer and allowing the other components to dissolve in the melt thereby preparing a homogeneous melt of said active ingredient(s), said pharmaceutically acceptable polymer(s) and said solubilizing composition, and
b) allowing the melt to solidify to obtain a solid dispersion product.

18. The method of claim 17 , additionally comprising grinding said solid dispersion product and compressing said solid dispersion product into a tablet.

19. The method of claim 17 , additionally comprising grinding said solid dispersion product and filling said solid dispersion product into a capsule shell.

20. The method of claim 17 , wherein the melt is shaped into a film or a foam before being allowed to solidify.

Assignees

• Abbvie Deutschland

Inventors

• Rosenberg Jörg
• Breitenbach Jörg
• Marsh Kennan
• Liepold Bernd
• Schmidt Christoph
• Lander Ute

Classifications

• A61P31/18

  for HIV · CPC title

• A61K9/145

  with organic compounds · CPC title

• A61K9/4833

  Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07) · CPC title

• A61K9/2013

  Organic compounds, e.g. phospholipids, fats · CPC title

• A61K9/2027

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title